To explore whether hyperactivation of the PI3K/AKT pathway following trametinib treatment is a robust phenomenon, we determined pAKT in response to trametinib in three additional HNSCC cell lines (HSC4, FADU, and CAL27). Here, AKT1 is linked to head and neck squamous cell carcinoma.